Karmazyn M
Department of Pharmacology and Toxicology, University of Western Ontario, London, Ontario, Canada.
J Thromb Thrombolysis. 1999 Jul;8(1):33-8. doi: 10.1023/a:1008990530176.
Sodium-hydrogen exchange (Na-H exchange) is a major regulator of intracellular pH and is one of the major mechanisms for restoring pH after ischemia-induced intracellular acidosis. However, activation of Na-H exchange during ischemia and reperfusion is also involved in paradoxical induction of cell injury. This likely reflects the fact that activation of the exchanger is closely coupled to sodium influx and, as a consequence, to elevation in intracellular calcium concentrations through sodium-calcium exchange. In addition to intracellular acidosis, other factors can also stimulate the exchanger, including various autocrine and paracrine factors, such as endothelin-1, angiotensin II, alpha(1)-adrenergic agonists, as well as toxic agents, such as hydrogen peroxide and lysophosphatidylcholine. Although at least six Na-H exchange isoforms have thus far been identified, it appears that the 1 subtype, termed NHE1, is the predominant isoform in the mammalian myocardium. Effective pharmacological inhibitors of Na-H exchange, including those that are NHE1 specific, have been extensively demonstrated to protect the ischemic and reperfused myocardium in terms of improved systolic and diastolic function, preservation of cellular ultrastructure, attenuation of the incidence of arrhythmias, and reduction of apoptosis. Moreover, the salutary effects of these agents have been demonstrated using a variety of experimental models as well as animal species, suggesting that the role of Na-H exchange in mediating injury is not species specific. Thus, Na-H exchange represents an important target for pharmacological intervention in attenuation of ischemia and reperfusion-induced cardiac injury. Coupled with the low potential for toxicity of the agents, Na-H exchange inhibition could emerge as an effective therapeutic strategy in cardiac disorders, particularly involving conditions associated with ischemia and reperfusion.
钠氢交换(Na-H交换)是细胞内pH值的主要调节因子,也是缺血诱导的细胞内酸中毒后恢复pH值的主要机制之一。然而,缺血和再灌注期间Na-H交换的激活也参与了细胞损伤的反常诱导。这可能反映了这样一个事实,即交换体的激活与钠内流密切相关,因此与通过钠钙交换导致的细胞内钙浓度升高密切相关。除细胞内酸中毒外,其他因素也可刺激交换体,包括各种自分泌和旁分泌因子,如内皮素-1、血管紧张素II、α1肾上腺素能激动剂,以及有毒物质,如过氧化氢和溶血磷脂酰胆碱。尽管迄今为止已鉴定出至少六种钠氢交换亚型,但似乎1亚型(称为NHE1)是哺乳动物心肌中的主要亚型。钠氢交换的有效药理学抑制剂,包括那些对NHE1具有特异性的抑制剂,已被广泛证明在改善收缩和舒张功能、保存细胞超微结构、降低心律失常发生率以及减少细胞凋亡方面对缺血和再灌注心肌具有保护作用。此外,这些药物的有益作用已在多种实验模型以及动物物种中得到证实,这表明钠氢交换在介导损伤中的作用并非物种特异性。因此,钠氢交换是减轻缺血和再灌注诱导的心脏损伤的药理学干预的重要靶点。再加上这些药物的低毒性潜力,钠氢交换抑制可能成为治疗心脏疾病,特别是涉及与缺血和再灌注相关病症的有效治疗策略。